Runcie Chidebe: 10 Years of Global Advocacy and Awareness for Ovarian Cancer
Runcie C.W. Chidebe/LinkedIn

Runcie Chidebe: 10 Years of Global Advocacy and Awareness for Ovarian Cancer

Runcie Chidebe, Education Administrative College Intern – Interprofessional Learning at Cleveland Clinic, shared on LinkedIn:

“I am in Montreal, Canada for the World Ovarian Cancer Coalition Board Meeting and Summit.

For the past 10 years, the World Ovarian Cancer Coalition has been leading global advocacy and awareness on ovarian cancer using evidence and other means to demystify the pains of women.

I am so excited to be part of this movement and so proud to see the progress of the work that the incredible staff, board and partners have done over the years.

Thanks to all donors, sponsors and partners who trusted World Ovarian Cancer Coalition. Special thanks to patients who are using their pains for the gain our communities and have been leading and guiding the coalition. We have done a lot, but there is still more work to be done in Ovarian Cancer.

Women in low- and middle-income countries (LMICs) account for 70% of ovarian cancer cases. We have seen a lot women surviving ovarian cancer in high income countries, but in most LMICs women with ovarian cancer are dying daily. They rarely have access to the most basic treatment- even pain medication is difficult to access. Ovarian cancer patients are still largely stigmatized in most LMICs. Government investment in ovarian cancer is still weak and most policies are tilted for other healthcare needs.

Women’s health is attractive for political campaigns but not reflected in the actual health policies and investment. Every one of us is a fruit of an ovary, lets all commit to save our women.

No woman should be left behind. Here to meet, analyze, deliberate and plan for strategies and approaches needed to reduce the burden of ovarian cancer globally. Let’s do more!

Thanks to my board chair Robin Cohen and the board members for their commitment and hard work.”

This also can be interesting:

Botensilimab Plus Balstilimab Shows 48% Estimated Three-Year Survival in Recurrent Ovarian Cancer at IGCS 2026

Runcie Chidebe: 10 Years of Global Advocacy and Awareness for Ovarian Cancer